PACE-CME

Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis

Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
RestartResume
3' education - May 25, 2023 - Marianna Fontana, MD, PhD
  • Overview

    ESC HF 2023 What are the results of an open-label extension study of the APOLLO-B trial with patisiran in patients with ATTR cardiac amyloidosis? Prof. Fontana provides a brief summary.

  • Educational information

    This video was recorded during the ESC Heart Failure 2023 in Prague, Czech Republic.

  • Faculty

    Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, VK.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of this interim analysis

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free